Weekly Report on Big Health Industry Investment and Financing (20250407)

【Ophthalmology Innovative Drugs】Ruijian Huitong is an ophthalmic innovative drug developer, established in 2025, focusing on the research and development of innovative drugs in the ophthalmology field. Currently, two core product pipelines under intensive research are both first-in-class innovative drugs with global patents. The clinical application pathway follows FDA-NMPA dual submission, and extensive IT studies have been conducted.

【Investor】SDVC, Qianhai Mother Fund

【Nucleic Acid Drugs】NEWISH is an innovative drug company focused on the early treatment of tumors and has entered the clinical stage, concentrating on the development of First-in-Class new drugs with full independent intellectual property rights. It has now jointly established the STARi nucleic acid drug development technology platform with Academician Jiang Jian Dong, focusing on addressing unmet clinical needs and striving to become a global leader in the research and development of new drugs for early tumor treatment. The STARi technology platform – a nucleic acid drug platform that strongly targets and activates T-cell immune responses, used for developing various tumor vaccine products; the NewishT cell therapy platform, autologous memory lymphocyte injection – the world’s first cell therapy product approved by national regulatory authorities with central memory T cells as the main component, used to prevent recurrence after various solid tumor surgeries. The company has formed an outstanding research team and an efficient registration team consisting of academicians, researchers, doctors, masters, and senior industry experts. It has obtained more than 40 invention patents, published six SCI papers, and received funding support from major science and technology projects.

【Investor】Xichuang Investment

【Recombinant Collagen】Jiangsu Jland Biotech Co., Ltd. is a high-tech enterprise specializing in the industrial design and application of biomimetic recombinant functional proteins. With top-notch bioengineering technologies such as genetic recombination, microbial fermentation, and protein separation and purification, it has established scalable production processes for various functional proteins. The company focuses on the industrial design and application of biomimetic recombinant proteins, deeply engaging in collagen technology research and the development of downstream products. By utilizing bioengineering technologies like genetic recombination and microbial fermentation, it has successfully achieved large-scale production of multiple functional proteins. Its products cover a wide range of fields including pharmaceuticals, medical devices, medical aesthetics, tissue regeneration, and organ transplantation, demonstrating broad application prospects. It is one of the largest suppliers of recombinant collagen globally. In 2024, Jiangsu Jland Biotech Co., Ltd.'s food-grade recombinant collagen received FDA approval in the United States, allowing its oral beauty products to legally enter the European and American markets.

【Investor】Yuexiu Industrial Fund, SDIC Capital

【PET Tracer】Hangzhou Jirui Technology Co., Ltd. is a company focused on the automated synthesis instrument for nuclear medicine molecular imaging tracers, OnePlatform®. Utilizing the OnePlatform® synthesis platform, the company has completed the research and development of scientific research equipment (used for drug screening) and radiopharmaceutical production equipment (including metal modules), achieving a multi-series product layout in hospitals, radiopharmacies, scientific research institutes, and radiopharmaceutical enterprises. The company has realized the localization of China-produced one-touch multifunctional automated synthesis equipment for nuclear medicine PET tracers for the first time. Positron Emission Tomography (PET) is an advanced clinical imaging technology that plays a crucial role in the early diagnosis, lesion localization, tracking of metastases and primary lesions, and efficacy evaluation of cancers, cardiovascular diseases, and neurological disorders.

【Investor】Qiu Shi Capital, Taiyu Investment, Xiongkai Group

【Intelligent Lumbar Rehabilitation Equipment】Cashew Intelligence is a company specializing in the research and development of intelligent lumbar rehabilitation devices, focusing on lumbar health. By integrating artificial intelligence technology with internationally renowned rehabilitation therapies, it develops home-based smart rehabilitation equipment. Its core product, the Cashew L1 Prone Chair, achieves precise lumbar stretching and fascia relaxation through AI dynamic adjustment. Centered around "AI + Rehabilitation Medicine," the company has miniaturized rehabilitation equipment worth 300,000 yuan, equipped with memory foam meeting EU standards and silent motors, supporting a load of 120 kilograms and adapting to users of different body types. The product incorporates the McKenzie Method, enabling self-guided rehabilitation training via a mini-program to alleviate issues such as lumbar bulging and herniation.

【Investor】Zhuhai Yuewan Huasheng

【Neurosurgical Medical Devices】CRAIN Research Institute is a medical device R&D and sales company, and a high-tech enterprise in the medical device industry that integrates independent innovation R&D, large-scale production, and professional marketing. It focuses on developing a series of neurosurgical products to enhance product quality and service levels.

【Investor】Timely Rain Investment

【Pen Injector】Baojuhe Medical focuses on the process research of "self-administration devices" in the healthcare industry and provides comprehensive solutions, serving global customers through technological innovation. The company gathers top talents in the self-administration device industry, offering not only product development for "self-administration devices," but also providing instrument and device systems related to self-administration throughout the entire process from drug development to clinical trials. It has successfully developed multiple disposable injection pens such as LoonGBIOPen® and Beinghigher®, which are being validated in collaboration with several pharmaceutical companies. The LoonGBIOPen® has already received tens of millions of intent orders. All products are independently developed with proprietary invention patents, compatible with all pre-filled injection drugs, and feature a wide range of application scenarios. In the second half of 2024, the company completed the registration of its first injection pen as pharmaceutical packaging material with the National Medical Products Administration (NMPA), and by the end of April 2025, it will complete the NMPA registration for three models of pens.

【Investor】Dandelion Ventures, Xinda Nuocheng Ventures, Xinqi Industrial Investment, Dandelion Jiangnan Ventures

【Electrophysiology】Xuanyu Medical was founded in May 2020 and is located in Shanghai's Zhangjiang High-Tech Core Park. With over 20 patents, it is an innovative medical device company in China that leads in the dual-platform layout of electrophysiology and peripheral intervention. The company’s self-developed multi-channel cardiac pulsed field ablation system consists of the SHINERHYTHM® multi-channel cardiac pulsed field ablation instrument and the RHYTHPULSE® single-use cardiac pulsed field ablation catheter. It is compatible with mainstream 3D cardiac electrophysiological mapping systems and is primarily used for treating rapid arrhythmias. The RHYTHPULSE® multi-channel pulsed field ablation system officially received NMPA approval for marketing on February 26, 2025, becoming the first domestically produced PFA system approved in China to integrate multi-channel, large focal, and targeted ablation. In addition to the electrophysiology field, the company has also made smooth progress in peripheral vascular intervention. Self-developed products such as the VariSeal® venous closure system and the pulmonary artery thrombectomy stent system have achieved breakthrough progress, while the polyvinyl alcohol embolic microspheres developed in collaboration have been successfully approved for marketing. Currently, the company’s atrial fibrillation pulsed field ablation system and venous closure system have completed preclinical validation and entered the clinical registration research phase.

【Investor】Wuhan Yifeng Venture Capital, Baiyun Financial Holdings

【Cosmetic Ingredients】Beijing Shangjie Youlan Technology Co., Ltd. was established in December 2020. It is a technology-based company with multiple exclusive patents, mainly focusing on the development of new national-level cosmetic raw materials. The company utilizes a unique business model of using new national-level raw materials to enter the daily chemical product raw material market through "new replacing old," "new promoting old," "mutual growth of new and old," and "integration of new and old." This approach has gained recognition and support from multiple investment institutions in China. The company aims to comprehensively build itself into a comprehensive service provider for technology-based daily chemical product raw materials, with the potential to break the long-standing dominance of foreign raw material companies.

【Investor】Beijing Changping Science and Technology Industry Fund, China-US Green Fund, Shanghai Jiacheng Investment

【mRNA Upstream Raw Materials】Shenji Biotech, established in 2018, focuses on providing comprehensive upstream raw material solutions in the life sciences field. The company's core team originates from a Nanjing University doctoral group in chemical biology, with a strong technical background in chemical biology. Over the years, they have been dedicated to the research and industrialization of critical raw materials in life sciences. The company has developed several technological platforms, including antibody discovery, mRNA bulk solution preparation, mRNA-LNP formulation processes, oligonucleotide preparation, and enzyme-directed evolution. These advancements have led to three major product categories: raw materials for cell and gene therapy, raw materials for genetic nucleic acid drugs, and IVD raw materials.

【Investor】Suzhou Lingjun Venture Capital